#348 ‒ Women's sexual health, menopause, and hormone replacement therapy (HRT) | Rachel Rubin, M.D.

Episode Summary

Executive Summary: Peter Attia and Dr. Rachel Rubin make the case that women’s sexual and menopausal health is profoundly underdiagnosed, undertreated, and mis-taught in medicine. They review ovarian hormone physiology, the harms of menopause, the fallout from misreading the Women’s Health Initiative, and a practical, individualized approach to systemic and local hormone therapy—including testosterone and vaginal estrogen/DHEA—as a high-value, evidence-based way to improve quality of life and reduce disease risk.

Main Topics: Menopause and perimenopause physiology (Priority: 5/5): Rubin explains the cyclic rise and fall of estrogen, progesterone, FSH, LH, and testosterone, emphasizing that perimenopause is defined by erratic hormonal volatility rather than a smooth decline. She uses the 'gas tank' analogy to explain symptoms driven by both hormonal highs and lows. Risks of untreated menopause (Priority: 5/5): The conversation highlights that menopause affects far more than hot flashes: it increases risk of osteoporosis, cardiovascular disease, dementia, recurrent UTIs, pelvic/genitourinary symptoms, mood disruption, and sexual dysfunction. Women’s Health Initiative and HRT misinformation (Priority: 5/5): A major theme is that the WHI used a specific synthetic hormone regimen, was overinterpreted, and triggered decades of fear-based medicine that led many clinicians to stop prescribing hormones and deprived millions of women of benefits. Practical hormone replacement strategy (Priority: 4/5): Rubin and Attia discuss individualized prescribing: estradiol delivery options (patch, gel, ring, oral), progesterone choices for women with a uterus, and when testosterone should be added. They stress using symptoms plus labs, not one-size-fits-all rules. Testosterone in women’s health (Priority: 4/5): Rubin argues testosterone is underrecognized in women, declines with age, and has evidence for improving low libido and possibly other symptoms such as urinary, mood, and arousal issues. She prefers low-dose topical male formulations rather than pellets. Local vaginal therapy for GSM and UTI prevention (Priority: 5/5): They emphasize vaginal estrogen and vaginal DHEA as safe, inexpensive, and underused therapies for genitourinary syndrome of menopause, pain with sex, urinary urgency/frequency, incontinence, and recurrent UTIs, including in high-risk women. Medical training gaps and commercial exploitation (Priority: 4/5): Both speakers criticize the lack of menopause education in mainstream medicine, which creates a vacuum filled by low-quality cash-pay clinics, compounded/pellet practices, and misinformation. They call for more clinician training and better access to validated care.

Key Arguments: Perimenopause is not a gentle decline; it is hormonal chaos with large swings in estradiol and progesterone that can drive symptoms even when labs look normal on a single day. Menopause is a whole-body endocrine event, not just a hot-flash problem; the loss of hormones affects brain, bone, heart, urinary tract, musculoskeletal system, and sexual function. The WHI was widely misread: it studied one synthetic regimen, not modern estradiol/progesterone options, and its relative-risk framing caused outsized fear compared with the small absolute risk increase. The risk of not treating menopause is substantial and should be weighed as seriously as medication risks, especially for fractures, cardiovascular disease, UTIs, and quality of life. Testosterone matters in women and is often ignored; low-dose topical testosterone can restore libido and sometimes improve urinary and sexual symptoms without dramatic virilization when dosed appropriately. Vaginal estrogen and vaginal DHEA are highly effective local therapies for GSM and recurrent UTIs, with minimal systemic absorption, and should be used even in many women who cannot or do not want systemic hormones. Hormone prescribing should be individualized: route, dose, timing, and combinations should be tailored to symptoms, risk factors, and patient preferences rather than dogmatic rules. A major barrier is not just misinformation but clinician inexperience; many doctors do not know how to prescribe menopause therapies, pushing women toward fringe, expensive, and sometimes unsafe alternatives.

Data Points: Women on hormone therapy: Less than 4% - Rubin says fewer than 4% of women are currently on hormone therapy, despite many being eligible or symptomatic. Menopause education in training: Less than 6% - Rubin states fewer than 6% of internal medicine, OBGYN, or family practice doctors get even an hour of menopause education. WHI relative breast cancer increase: 24% - Attia notes the combined estrogen-progestin arm was reported as a 24% relative increase in breast cancer incidence. WHI absolute breast cancer increase: 0.1% - Attia emphasizes the absolute risk increase was about 0.1%, or roughly 1 additional case per 1,000 women. Estimated women deprived of HRT: More than 20 million - Attia estimates that decades of fear after WHI deprived more than 20 million women of benefit from HRT. UTI risk reduction with vaginal hormones: More than half - Rubin repeatedly states vaginal estrogen and vaginal DHEA reduce recurrent UTIs by more than 50%. Medicare savings from vaginal estrogen: $6 to $22 billion per year - Rubin cites a published estimate that universal use of vaginal estrogen in Medicare-eligible women could save Medicare billions annually. WHI study cost: About $1 billion - Rubin describes the Women’s Health Initiative as a billion-dollar study. WHI follow-up outcome window: Five years of data requested for testosterone approval - Rubin contrasts the five-year safety study demanded for women’s testosterone with the shorter pathway used for men. Topical testosterone dose used for women: About one-tenth of the male dose - Rubin explains she uses FDA-approved male testosterone gel in roughly one-tenth male dosing for women. Progesterone starting dose: 100 mg daily - Rubin says she typically starts oral micronized progesterone at 100 mg daily, with cyclic 200 mg as another common regimen. Progesterone cyclic regimen: 200 mg for 12–14 days/month - Rubin describes an alternative cyclic progesterone schedule used by many menopause specialists. Systemic estradiol on ring: 0.05 or 0.1 mg Femring - Rubin distinguishes the higher-dose systemic ring from the low-dose vaginal ring. Local vaginal estradiol ring: 2 mg Estring - Rubin notes Estring is a low-dose local therapy for GSM, not for hot flashes or bone protection. Compounded vestibular cream example: 0.01% estradiol + 0.1% testosterone - Rubin describes a compounded vulvar vestibule formula used when estrogen alone is insufficient for pain with sex or urinary symptoms.

Pivotal Quotes: "Menopause is sort of a your gas tank is officially empty." — Dr. Rachel Rubin: Rubin uses this metaphor to explain the abrupt loss of ovarian hormones and the symptoms women experience. "We scared an entire generation of people away from hormones because of a bad misinterpretation of statistics." — Dr. Rachel Rubin: Her summary of how the WHI influenced decades of fear-based prescribing and under-treatment. "Vaginal hormones should not be gynecology. It should not be a small subset of menopause medicine." — Dr. Rachel Rubin: Rubin argues local estrogen therapy is mainstream whole-body preventive care, especially for urinary tract protection.

Implications: Listeners should understand menopause care as evidence-based preventive medicine, not optional comfort care. The field needs better clinician training, broader access to validated therapies, and less fear-driven prescribing so women can get effective, individualized treatment.